Pirfenidone treatment of idiopathic pulmonary fibrosis

Therapeutic Advances in Respiratory Disease

Volumn 6, Issue 2, 2012, Pages 107-114

  Azuma, Arata ^a  

^a NIPPON MEDICAL SCHOOL   (Japan)

Author keywords

antifibrotic; evidence based (EB) guideline; idiopathic pulmonary fibrosis; phenostage; pirfenidone; prognostic factor; vital capacity

Indexed keywords

PIRESPA; PIRFENIDONE; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG;

ANOREXIA; BLOOD OXYGEN TENSION; DISEASE COURSE; DRUG ACTIVITY; DRUG EFFECT; DRUG EFFICACY; DRUG MEGADOSE; ENZYME INHIBITION; FIBROSING ALVEOLITIS; FORCED EXPIRATORY FLOW; FORCED VITAL CAPACITY; HUMAN; LOW DRUG DOSE; META ANALYSIS; MORTALITY; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHOTOSENSITIVITY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; REVIEW; TOTAL LUNG CAPACITY;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CLINICAL TRIALS AS TOPIC; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; PYRIDONES; VITAL CAPACITY;

EID: 84859334535     PISSN: 17534658     EISSN: 17534666     Source Type: Journal    
DOI: 10.1177/1753465812436663     Document Type: Review

References (28)

1. American Thoracic Society. (2000) Idiopathic pulmonary fibrosis: diagnosis and treatment: international consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS). Am J Respir Crit Care Med 161: 646–664.
2. Azuma A. (2010) Pirfenidone: antifibrotic agent for idiopathic pulmonary fibrosis. Exp Rev Resp Med 4: 301–310.
3. Azuma A. Nukiwa T. Tsuboi E. Suga M. Abe S. Nakata K. (2005) Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 171: 1040–1047.
4. Azuma A. Taguchi Y. Ogura T. Ebina M. Taniguchi H. Kondoh Y. for the Pirfenidone Clinical Study Group in Japan (2011) Exploratory analysis of a phase III trial of pirfenidone identifies a subpopulation of patients with idiopathic pulmonary fibrosis as benefiting from treatment. Respir Res 12: 143.
5. Cottin V. Nunes H. Brillet P.-Y. Delaval P. Devouassoux G. Tillie-Leblond I. (2005) Combined pulmonary fibrosis and emphysema: a distinct underrecognised entity. Eur Respir J 26: 586–593.
6. du Bois R.M. Weycker D. Albera C. Bradford W.Z. Costabel U. Kartasho A. (2011) Ascertainment of individual risk of mortality for patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 184: 459–466.
7. Fletcher C.M. (1952) The clinical diagnosis of pulmonary emphysema; an experimental study. Proc Royal Soc Med 45: 577–584.
8. Gahl W.A Brantly M. Troendle J. Avila N.A. Padua A. Montalvo C. (2002) Effect of pirfenidone on the pulmonary fibrosis of Hermansky–Pudlak syndrome. Mol Genet Metab 76: 234–242.
9. Homma S. Azuma A. Taniguchi H. Ogura T. Mochiduki Y. Sugiyama Y. for the Japan NAC Clinical Study Group (2011). Efficacy of inhaled N-acetylcysteine monotherapy in patients with early stage idiopathic pulmonary fibrosis. Respirology [Epub ahead of print 18 January2012 DOI: 10.1111/j1440-184310.1111/j1440-1843].
10. Homma Y. Saiki S. Doi O. Yondea H. Mikami R. Tamura M. (1992) Clinical Diagnostic Criteria for Idiopathic Interstitial Pneumonia (3rd Revised Ed.). Diffuse Pulmonary Disease Research Group's, The Ministry of Health and Welfare of Japan, Japan, pp. 83–88.
11. Japanese Respiratory Society, Committee for Formulation of Diffuse Pulmonary Disease Diagnosis and Treatment Guidelines (2004) Idiopathic Interstitial Pneumonias ’ Guide to Diagnosis and Treatment. Tokyo: Nankodo (in Japanese).
12. King T.E. Jr Albera C. Bradford W.Z. (2009) Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebo-controlled trial. Lancet 374: 222–228.
13. Margolin S.B. Lefkowitz S. (1994) Pirfenidone: A novel pharmacologic agent for prevention and resolution (removal) of lung fibrosis. FASEB J 8: A382.
14. McGrath E.E. Millar A.B. (2011) Hot off the breath: triple therapy for idiopathic pulmonary fibrosis–hear the PANTHER roar. Thorax, DOI: 10.1136/thoraxjnl-2011-2013910.1136/thoraxjnl-2011-20139.
15. Nagai S. Hamada K. Shigematsu M. Taniyama M. Yamauchi S. Izumi T. (2002) Open-label compassionate use one year-treatment with pirfenidone to patients with chronic pulmonary fibrosis. Intern Med 41: 1118–1123.
16. Noble P.W. Albera C. Bradford W.Z. Costabel U. Glassberg M.K. Kardatzke D. for the CAPACITY Study Group. (2011) Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet 377: 1760–1769.
17. Oku H. (2009). A novel antifibrotic agent pirfenidone, 1) Antifibrotic mechanism of pirfenidone. Medicine Drug J 45: 120–125.
18. Oku H. Nakazato H. Horikawa T. Tsuruta Y. Suzuki R. (2002) Pirfenidone suppresses tumor necrosis factor-alpha, enhances interleukin-10 and protects mice from endotoxic shock. Eur J Pharmacol 446: 167–176.
19. Oku H. Shimizu T. Kawabata T. Nagira M. Hikita I. Ueyama A. (2008) Antifibrotic action of pirfenidone and prednisolone: Different effects on pulmonary cytokines and growth factors in bleomycin-induced murine pulmonary fibrosis. Eur J Pharmacol 590: 400–408.
20. Raghu G. Collard H.R. Egan J.J. Martinez F.J. Behr J. Brown K.K. on behalf of the ATS/ERS/JRS/ALAT Committee on Idiopathic Pulmonary Fibrosis. (2011) An Official ATS/ERS/JRS/ALAT Statement: Idiopathic Pulmonary Fibrosis: Evidence. Am J Respir Crit Care Med 183: 788–824.
21. Raghu G. Johnson W.C. Lockhart D. Mageto Y. (1999) Treatment of idiopathic pulmonary fibrosis with a new antifibrotic agent, pirfenidone: results of a prospective, open-label Phase II study. Am J Respir Crit Care Med 159: 1061–1069.
22. Richeldi L. du Bois R.M. (2011) Pirfenidone in idiopathic pulmonary fibrosis: the CAPACITY program. Expert Rev Respir Med 5: 473–481.
23. Schaefer C.J. Ruhrmund D.W. Pan L. Seiwert S.D. Kossen K. (2011) Antifibrotic activities of pirfenidone in animal models. Eur Respir Rev 20: 85–97.
24. Shionogi & Co. Ltd. (2008) Immunosuppressive Effect of Pirfenidone. Internal Data Reference No. 200801771, Shionogi and Co., Ltd (in Japanese).
25. Spagnolo P. Del Giovane C. Luppi F. Cerri S. Balduzzi S. Walters E.H. (2010) Non-steroid agents for idiopathic pulmonary fibrosis. Cochrane Database Syst Rev 9: CD003134.
26. Taniguchi H. Ebina M. Knodoh Y. Ogura T. Azuma A. Suga M. for the Pirfenidone Clinical Study Group in Japan. (2010) Pirfenidone in idiopathic pulmonary fibrosis. Eur Respir J 35: 821–829.
27. Taniguchi H. Kondoh Y. Ebina M. Azuma A. Ogura T. Taguchi Y. for the Pirfenidone Clinical Study Group in Japan. (2011) The clinical significance of 5% change in vital capacity in patients with idiopathic pulmonary fibrosis: extended analysis of the pirfenidone trial. Respir Res 12: 93.
28. Zappala C.J. Latsi P.I. Nicholson A.G. Colby T.V. Cramer D. Renzoni E.A. (2010) Marginal decline in forced vital capacity is associated with a poor outcome in idiopathic pulmonary fibrosis. Eur Respir J 35: 830–835.